Table 1 Clinical and biochemical data of examined patients.

From: A novel prognostic index—neutrophil times γ-glutamyl transpeptidase to lymphocyte ratio (NγLR) predicts outcome for patients with hepatocellular carcinoma

Parameter

Training cohort

Validation cohort

P value

(n = 463)

(n = 261)

Age (years)

50.14 ± 11.58

49.56 ± 10.84

0.504

Gender: female/male (n)

62/401

38/223

0.662

Family history: absent/present (n)

400/63

220/41

0.439

Drinking: absent/present (n)

245/218

153/108

0.138

Smoking: absent/present (n)

249/214

167/94

0.008

Cirrhosis: absent/present (n)

30/433

17/244

0.986

HBsAg: negative/positive (n)

68/395

45/216

0.363

HCVAb: negative/positive (n)

454/9

251/10

0.127

MaI: absent/present (n)

381/82

200/61

0.066

NγLR: median, range

137.54, 15.02–1507.96

133.59, 16.73–1236.02

0.746

SII: median, range

327.63, 5.72–2260.07

318.50, 4.35–2168.96

0.833

ALRI: median, range

24.65, 2.47–417.12

23.31, 0.94–320.96

0.540

WBC (×109/L)

6.15 ± 1.99

6.23 ± 2.00

0.598

NEUT (×109/L)

3.74 ± 1.70

3.80 ± 1.64

0.677

LYMPH (×109/L)

1.70 ± 0.63

1.72 ± 0.58

0.685

Platelets (×109/L)

175.62 ± 79.28

185.04 ± 82.63

0.131

Albumin (g/L)

39.17 ± 4.46

39.13 ± 4.34

0.915

Globulin (g/L)

30.87 ± 5.29

31.21 ± 4.96

0.388

TBIL (μmol/L)

17.82 ± 33.40

18.86 ± 41.06

0.719

DBIL (μmol/L)

7.94 ± 24.72

8.13 ± 25.05

0.850

ALT (U/L)

47.55 ± 43.51

45.39 ± 46.75

0.369

AST (U/L)

54.22 ± 55.06

53.69 ± 57.51

0.801

AFP (ng/ml): median, range

152.33, 0.23–11602.00

161.25, 0.61–10340.00

0.549

γ-GT (U/L): median, range

68.60, 10.00–657.30

67.50, 15.10–604.90

0.902

Use of NAs: absent/present (n)

310/93

181/44

0.306

Tumor size (cm)

7.82 ± 4.77

7.43 ± 4.65

0.183

Tumor number: single/multiple (n)

327/136

200/61

0.081

Tumor differentiation: I/II/III/IV (n)

61/180/178/44

43/89/91/38

0.085

Child-Pugh classification: A/B (n)

425/38

237/24

0.648

BCLC stage: 0/A/B/C (n)

20/232/116/95

18/127/78/38

0.076

Type of surgical resectiona (Anatomical/non-anatomical)

282/181

165/96

0.539

  1. aAnatomical resection includes hemihepatectomy, sectorectomy, and segmentectomy; non-anatomical resection includes limited resection and tumor enucleation. n, number of patients; HBsAg, hepatitis B surface antigen; HCVAb, hepatitis C virus antibody; MaI, microvascular invasion; NγLR, neutrophil cell count times γ-glutamyl transpeptidase to lymphocyte count ratio; SII, systemic immune-inflammation index; ALRI, aspartate transaminase to lymphocyte ratio index; WBC, white blood cell; LYMPH, lymphocyte count; TBIL, total bilirubin; DBIL, direct bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AFP, alpha-fetoprotein; γ-GT, γ-glutamyl transpeptidase; NAs, nucleoside analogues; BCLC, barcelona-clinic liver cancer.
Back to article page